openPR Logo
Press release

Calciphylaxis Market Poised for Notable Growth Through 2032, Driven by Rising Disease Awareness and Emerging Targeted Therapies | DelveInsight

05-08-2025 02:28 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Calciphylaxis Market Report

Calciphylaxis Market Report

The calciphylaxis treatment market is poised for notable growth, fueled by increasing disease recognition, growing prevalence among end-stage renal disease patients, and the advancement of innovative therapies by key players, including Amgen, AbbVie, Pfizer, Sanofi, Keryx Biopharmaceuticals, Ardelyx, Mallinckrodt Pharmaceuticals, Hope Pharmaceuticals, Sanifit, and Vifor Pharma, among others.
DelveInsight's "Calciphylaxis - Market Insight, Epidemiology And Market Forecast - 2032 [https://www.delveinsight.com/report-store/calciphylaxis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides a comprehensive analysis of historical and forecasted calciphylaxis epidemiological trends across the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. The report delivers valuable insights into calciphylaxis pathophysiology, current treatment practices, emerging therapies, and market dynamics that will shape the landscape over the next decade. This rare but devastating condition, characterized by painful skin lesions resulting from cutaneous arteriolar calcification, represents a significant unmet medical need with limited treatment options currently available.

According to DelveInsight analysis, the calciphylaxis treatment market is experiencing steady growth across 7MM, driven by a rising incidence of end-stage renal disease and associated risk factors like diabetes and obesity. Furthermore, the US is the largest market due to a high patient pool and ongoing innovation, while Europe and Japan are showing growth supported by advanced diagnostics and healthcare infrastructure.

Download the Calciphylaxis Market Forecast Report to understand which factors are driving the calciphylaxis market @ Calciphylaxis Market Trends [https://www.delveinsight.com/sample-request/calciphylaxis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

According to epidemiological findings highlighted in the report, calciphylaxis demonstrates a notable gender disparity, with significantly higher incidence rates among female patients. This gender-specific pattern provides important demographic insights for healthcare planning and therapeutic development strategies.

The report segments the calciphylaxis patient population across important categories, including total incident cases of calciphylaxis in patients on hemodialysis, overall incident cases, and gender-specific incident distribution. This granular analysis provides stakeholders with crucial insights for strategic planning and resource allocation in addressing this challenging rare disease.

Discover evolving trends in the calciphylaxis patient pool forecasts @ Calciphylaxis Epidemiological Analysis [https://www.delveinsight.com/sample-request/calciphylaxis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The current calciphylaxis treatment approach necessitates a multidisciplinary intervention focusing on optimal wound management, appropriate antibiotic therapy for secondary infections, correction of biochemical abnormalities, avoidance of cutaneous trauma, and administration of sodium thiosulfate. However, the disease continues to carry high mortality rates primarily due to sepsis complications, underscoring the urgent need for more effective therapeutic options that can specifically target the underlying calciphylaxis pathophysiological mechanisms.

The calciphylaxis clinical trial pipeline is showing growing activity, with several promising therapies in development. Key drugs currently in the pipeline include SNF472, INZ-701, and intravenous sodium thiosulfate, among others. SNF472, developed by Sanifit, is a selective inhibitor of vascular calcification and is currently in Phase III clinical trials (CALCIPHYX). INZ-701, an enzyme replacement therapy designed to increase plasma pyrophosphate levels, has demonstrated positive interim results in Phase I and is expected to enter registrational trials soon. Sodium thiosulfate, already widely used off-label, has been evaluated in the CALISTA Phase III trial to better understand its efficacy and safety for calciphylaxis in hemodialysis patients.

DelveInsight's analysis indicates that the calciphylaxis market is expected to witness significant expansion across the 7MM, driven by several key factors. These include the high prevalence of calciphylaxis in patients with end-stage renal disease, increasing disease awareness among healthcare providers, growing recognition of early symptoms, and the rising demand for effective treatment modalities. Additionally, advancements in diagnostic technologies driven by leading players such as Amgen (NASDAQ: AMGN), AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), Sanofi (NASDAQ: SNY), Keryx Biopharmaceuticals, Ardelyx (NASDAQ: ARDX), Mallinckrodt Pharmaceuticals (MNKTQ), and Vifor Pharma, among others, are enabling earlier and more accurate identification of calciphylaxis, contributing to market growth by expanding the treatable patient population.

Discover evolving trends in the calciphylaxis treatment landscape @ Calciphylaxis Recent Developments [https://www.delveinsight.com/sample-request/calciphylaxis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Looking ahead, the calciphylaxis market landscape is expected to evolve significantly with the potential approval of novel therapeutic options, increased disease awareness, and improved diagnostic approaches. The introduction of targeted treatments like SNF472 could substantially reduce mortality rates and improve quality of life for patients suffering from this debilitating condition. However, challenges remain, including the need for enhanced understanding of disease pathogenesis, the development of standardized treatment protocols, and addressing the economic burden associated with managing this complex condition.

Table of Contents

1. Key Insights

2. Report Introduction

3. Calciphylaxis: Market Overview at a Glance

4. Executive Summary of Calciphylaxis

5. Key Events

6. Epidemiology and Market Forecast Methodology

7. Calciphylaxis: Disease Background and Overview

8. Calciphylaxis Treatment

9. Calciphylaxis Epidemiology and Patient Population

10. Calciphylaxis Emerging Drugs

11. Calciphylaxis: Seven Major Market Analysis

12. KOL Views

13. SWOT Analysis

14. Calciphylaxis Unmet Needs

15. Reimbursement and Market Access of Calciphylaxis

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Related Reports

Calciphylaxis Pipeline Insight [https://www.delveinsight.com/sample-request/calciphylaxis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Calciphylaxis Pipeline Insight provides comprehensive insights about the calciphylaxis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the calciphylaxis companies, including Hope Pharmaceuticals, Sanifit, Alexion Pharmaceuticals, Epizon Pharma, and Rectify Pharma, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=calciphylaxis-market-poised-for-notable-growth-through-2032-driven-by-rising-disease-awareness-and-emerging-targeted-therapies-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Calciphylaxis Market Poised for Notable Growth Through 2032, Driven by Rising Disease Awareness and Emerging Targeted Therapies | DelveInsight here

News-ID: 4005953 • Views:

More Releases from ABNewswire

ABSSSI Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Glenmark Pharma, Melinta Therapeutics, Sandoz Inc, Paratek Pharma, AbbVie Inc., Allergan PLC, Merck & Co. Inc., Pfizer
ABSSSI Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Gl …
The Key Acute Bacterial Skin and Skin-Structure Infection Companies in the market include - Glenmark Pharmaceuticals Ltd, Melinta Therapeutics Inc., Sandoz Inc. (a subsidiary of Novartis), Paratek Pharmaceuticals Inc., AbbVie Inc. (Allergan PLC), Merck & Co. Inc., Pfizer Inc., Melinta Therapeutics Inc., MicuRx, Basilea Pharmaceuticals, Motif Bio, Wockhardt, Allergan, Basilea Pharma, and others. DelveInsight's "Acute Bacterial Skin and Skin-Structure Infection Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding
Breakthrough Magnetic Technology Saves 17 Decibels of Hearing Protection While Winning 2025 New Product Award
Breakthrough Magnetic Technology Saves 17 Decibels of Hearing Protection While W …
Magna Lens ComfortSafe Registered Magnetic Protective Eyewear receives prestigious 2025 New Product of the Year award from Occupational Health & Safety Magazine for revolutionary technology that preserves crucial hearing protection while eliminating painful pressure points. The patented magnetic design addresses critical safety gaps affecting tens of millions of workers who require both eye and hearing protection simultaneously. Magna Lens has achieved a significant milestone in workplace safety innovation with their ComfortSafe
K & G Immigration Law is expanding service offerings in Sacramento, California
K & G Immigration Law is expanding service offerings in Sacramento, California
Sacramento, CA - October 1st, 2025 - Due to the increased need for reliable legal representation of multicultural and multilingual immigrant communities of Sacramento County in California, K & G Law LLP [https://www.kgimmigrationlaw.com] is expanding its operations, location, and team in this market to meet current demand and accommodate clients' needs. The firm is moving to a larger and better-located office, expanding the number of experienced immigration attorneys in Sacramento, and
Aniioki 2-in-1 Charger: A World-First Innovation, Ushering in a New Era of Outdoor Power
Aniioki 2-in-1 Charger: A World-First Innovation, Ushering in a New Era of Outdo …
In the realm of outdoor adventures and family emergencies, power supply has long been an invisible barrier to freedom and comfort. Now, Aniioki, a pioneer in long-range e-bikes and sustainable mobility, introduces a game-changing solution-the world's first 2-in-1 inverter + charger bidirectional device [https://s.attribuly.com/8dotVGpR]. This isn't just a technological leap; it's a breakthrough designed to redefine outdoor power and emergency energy use. Image: https://www.abnewswire.com/upload/2025/09/56bb4cec778e1dcb252ea17151359777.jpg "This product is not just about charging-it's about

All 5 Releases


More Releases for Calciphylaxis

Calciphylaxis Market Insights 2032: Competitive Landscape, Opportunities, and Gr …
Introduction: The calciphylaxis market is witnessing steady growth, driven by increasing awareness of this rare but severe condition, advancements in diagnostic techniques, and the development of novel therapeutic interventions. Calciphylaxis, also known as calcific uremic arteriolopathy (CUA), is a debilitating disease characterized by the calcification of small blood vessels in the skin and subcutaneous tissue, leading to painful skin lesions, ulceration, and a high risk of infection. The market's expansion is
Top Factor Driving Calciphylaxis Treatment Market Growth in 2025: Elevated Kidne …
What market dynamics are playing a key role in accelerating the growth of the calciphylaxis treatment market? The escalating incidences of kidney diseases can potentially fuel the growth of the market for calciphylaxis treatment. Various disorders and physical conditions that impact the kidneys, crucial organs that filter waste and excess fluids from the blood to create urine, are referred to as kidney diseases. These diseases interfere with the metabolism of calcium
Primary Catalyst Driving Calciphylaxis Treatment Market Evolution in 2025: Eleva …
What Is the Future Outlook for the Calciphylaxis Treatment Market's Size and Growth Rate? The calciphylaxis treatment market has seen rapid expansion in recent years. It is expected to grow from $1.86 billion in 2024 to $2.05 billion in 2025 at a CAGR of 10.4%. Factors contributing to past growth include a rising incidence of calciphylaxis, greater awareness among medical professionals, improvements in healthcare infrastructure, and advancements in clinical research and
Calciphylaxis Treatment Market Report 2024 - Calciphylaxis Treatment Market Size …
"The Business Research Company recently released a comprehensive report on the Global Calciphylaxis Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, the calciphylaxis treatment market
Calciphylaxis Treatment Market Report 2024 - Calciphylaxis Treatment Market Shar …
"The Business Research Company recently released a comprehensive report on the Global Calciphylaxis Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, The calciphylaxis treatment market
Calciphylaxis Market Report 2032 by DelveInsight | Hope Pharmaceuticals, Sanifit …
Calciphylaxis Market Report 2032 by DelveInsight | Hope Pharmaceuticals, Sanifit, and others DelveInsight's "Calciphylaxis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Calciphylaxis, historical and forecasted epidemiology as well as the Calciphylaxis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Calciphylaxis market report provides current treatment practices, emerging drugs, Calciphylaxis market share of the individual therapies, and current